Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03795038
Other study ID # TA-DMD-01-D
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date December 28, 2018
Est. completion date May 25, 2021

Study information

Verified date July 2022
Source Fresenius Medical Care Deutschland GmbH
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The clinical Investigation will be performed to compare the safety and effectiveness of the CE certified and established lipoprotein apheresis systems MONET vs. DALI and DIAMED vs. DALI for optimizing the individual therapy of patients with severe dyslipidemia using established and novel efficacy parameters.


Description:

Comparison of the safety and effectiveness of the CE certified and established lipoprotein apheresis systems MONET vs. DALI and DIAMED vs. DALI for optimizing the individual therapy of patients with severe dyslipidemia using established and novel efficacy parameters. The primary objective is to compare the whole blood lipoprotein apheresis system DALI with the plasma lipoprotein apheresis systems MONET and DIAMED with regard to their efficacies in removing total cholesterol, low density lipoprotein cholesterol (LDL-C), triglycerides and lipoprotein (a) (Lp(a)). The secondary objective is to compare the whole blood lipoprotein apheresis system DALI with the plasma lipoprotein apheresis system MONET and DIAMED with regard to their efficacies in removing other novel efficacy parameters.


Recruitment information / eligibility

Status Completed
Enrollment 20
Est. completion date May 25, 2021
Est. primary completion date May 25, 2021
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Informed consent signed and dated by study patient and investigator/authorised physician - Minimum age of 18 years - Ability to understand the nature and requirements of the study Study-specific inclusion criteria: - Patients with indication for lipoprotein apheresis confirmed by a local apheresis expert commission according to the German guidelines [1] and with routine lipoprotein apheresis treatments for at least 3 months. Patients with weekly treatments have not missed more than 3 treatment sessions within the 3 months prior inclusion to the study. Patients with biweekly treatment sessions have not missed more than 1 treatment session within the 3 months prior inclusion to the study - Patients with regular weekly or biweekly lipoprotein apheresis treatments with either MONET or DIAMED lipoprotein apheresis systems for at least 4 weeks (weekly treatments) or 8 weeks (biweekly treatments) with the same system - With adequate venous access - With systolic blood pressure > 100 mmHg - With stable hematocrit >35 % - With stable anticoagulation Exclusion Criteria: - Any condition which could interfere with the patient's ability to comply with the study - Pregnancy or lactation period (pregnancy test will be conducted with female patients aged 55 years) - Participation in an interventional clinical study during the preceding 30 days or in the same study Study-specific exclusion criteria: - Occurrence or clinical relevant deterioration of acute myocardial infarction, unstable angina pectoris, severe hemo-dynamic relevant arrhythmia within 3 months prior inclusion to the study - Bypass surgery, vascular diseases, active infection (this means chronic infectious diseases (e.g. chronic hepatitis) and acute infections with a core body temperature = 38.0 °C) or unstable circulation (see exclusion criteria no. 7) within the last 3 months - Uncontrolled high or low blood pressure defined as systolic blood pressure >180 mmHg/<100 mmHg and/or diastolic blood pressure >115 mmHg (after three times measuring) - Changes in lipid lowering medication within the last 2 weeks - Intake of Angiotensin Converting Enzyme (ACE) inhibitor medication within a time interval of five times the terminal half-life of the ACE inhibitor before study start and during the study - History of allergic reactions to anticoagulation

Study Design


Intervention

Device:
Lipoprotein Apheresis MONET and DALI
Three apheresis treatments assigned to one type of apheresis system of MONETand DALI
Lipoprotein Apheresis DIAMED and DALI
Three apheresis treatments assigned to one type of apheresis system of DIAMOND and DALI

Locations

Country Name City State
Germany Universitätsklinikum Carl Gustav Carus an der Technischen Universität Dresden Dresden Sachsen
Germany Nephrocare Rostock GmbH Rostock Mecklenburg-Vorpommern

Sponsors (1)

Lead Sponsor Collaborator
Fresenius Medical Care Deutschland GmbH

Country where clinical trial is conducted

Germany, 

Outcome

Type Measure Description Time frame Safety issue
Primary Removal rate of total cholesterol Removal rate of total cholesterol as primary endpoint in blood samples to evaluate the clinical performance of the apheresis systems every week for 6 weeks or biweekly for 12 weeks
Primary Removal rate of low density lipoprotein cholesterol (LDL-C) Removal rate of low density lipoprotein cholesterol (LDL-C) as primary endpoint in blood samples to evaluate the clinical performance of the apheresis systems every week for 6 weeks or biweekly for 12 weeks
Primary Removal rate of triglycerides Removal rate of triglycerides as primary endpoint in blood samples to evaluate the clinical performance of the apheresis systems every week for 6 weeks or biweekly for 12 weeks
Primary Removal rate of lipoprotein (a) (Lp(a)). Removal rate of lipoprotein (a) (Lp(a)) as primary endpoint in blood samples to evaluate the clinical performance of the apheresis systems every week for 6 weeks or biweekly for 12 weeks
See also
  Status Clinical Trial Phase
Recruiting NCT05654272 - Development of CIRC Technologies
Recruiting NCT05650307 - CV Imaging of Metabolic Interventions
Recruiting NCT04515303 - Digital Intervention Participation in DASH
Completed NCT04056208 - Pistachios Blood Sugar Control, Heart and Gut Health Phase 2
Recruiting NCT04417387 - The Genetics and Vascular Health Check Study (GENVASC) Aims to Help Determine Whether Gathering Genetic Information Can Improve the Prediction of Risk of Coronary Artery Disease (CAD)
Not yet recruiting NCT06211361 - Cardiac Rehabilitation Program in Patients With Cardiovascular Disease N/A
Not yet recruiting NCT06032572 - Evaluation of the Safety and Effectiveness of the VRS100 System in PCI (ESSENCE) N/A
Recruiting NCT04514445 - The BRAVE Study- The Identification of Genetic Variants Associated With Bicuspid Aortic Valve Using a Combination of Case-control and Family-based Approaches.
Enrolling by invitation NCT04253054 - Chinese Multi-provincial Cohort Study-Beijing Project
Completed NCT03273972 - INvestigating the Lowest Threshold of Vascular bENefits From LDL Lowering With a PCSK9 InhibiTor in healthY Volunteers N/A
Completed NCT03680638 - The Effect of Antioxidants on Skin Blood Flow During Local Heating Phase 1
Recruiting NCT04843891 - Evaluation of PET Probe [64]Cu-Macrin in Cardiovascular Disease, Cancer and Sarcoidosis. Phase 1
Completed NCT04083846 - Clinical Study to Investigate the Pharmacokinetic Profiles and Safety of High-dose CKD-385 in Healthy Volunteers(Fed) Phase 1
Completed NCT04083872 - Clinical Study to Investigate the Pharmacokinetic Profiles and Safety of Highdose CKD-385 in Healthy Volunteers(Fasting) Phase 1
Completed NCT03693365 - Fluid Responsiveness Tested by the Effective Pulmonary Blood Flow During a Positive End-expiratory Trial
Completed NCT03466333 - Postnatal Enalapril to Improve Cardiovascular fUnction Following Preterm Pre-eclampsia Phase 2
Completed NCT03619148 - The Incidence of Respiratory Symptoms Associated With the Use of HFNO N/A
Completed NCT04082585 - Total Health Improvement Program Research Project
Completed NCT05132998 - Impact of a Comprehensive Cardiac Rehabilitation Program Framework Among High Cardiovascular Risk Cancer Survivors N/A
Completed NCT05067114 - Solutions for Atrial Fibrillation Edvocacy (SAFE)